Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
The BioCentury Show
BioCentury
Marketing Over Coffee Marketing Podcast
John Wall and Christopher Penn
The Corporate Entrepreneur
Sue Gilenson, Marc Gilenson
Mindset Reloaded - Brian Tracy Motivation Daily
Motiv
Morning Wealth
THE STANDARD
FlavorVille Radio – Straight Outta the Kitchen (Premiere Episode)
Brian M Inspired
The Property Couch
Bryce Holdaway & Ben Kingsley
4biddenknowledge Podcast
Billy Carson 4biddenknowledge
ELANA 5 a.m. Club
ELANA Trading
Startup Insider
Startup Insider
CountryWide CONNECT
CountryWide Media
Flash Stock Reports (Video)
Flash by StockSentinel.AI
Bloomberg Law
Bloomberg
Desayuno con Bancolombia
Bancolombia
JIJI news for English Learners-時事通信英語学習ニュース‐
時事通信社
The Voice of Florida Architecture
AIA Florida
Die Potenzialwerkstatt
Andreas Nemeth - Der Potenzialentwickler
Alles auf Aktien – Die täglichen Finanzen-News
WELT
Morgenkaffen med Finansavisen
Finansavisen
Richissime
Delphine Pinon
Law, disrupted
Law, disrupted
Haken dran – das Social-Media-Update der c't
Gavin Karlmeier
Die Macht der Sprache – Psychologie für Copywriting, Branding und Verkauf
Youri Keifens
It’s A YP Thing Podcast
Pansy Johnson
Success Leaves Clues
Davis Nguyen
槓桿人生
Ivan
brand eins-Podcast
detektor.fm – Das Podcast-Radio
Valuetainment
Valuetainment
Ranní brífink
Hospodářské noviny
Medicare For The Lazy Man Podcast
Douglas B. Jones, CLU, RHU with Randy Carson of C2C Consulting
JIJI English News-時事通信英語ニュース-
時事通信社
Money News
Tapt Media
Audio-CD.at Indie Podcasts: Wiener Börse, Sport, Musik (und mehr)
Christian Drastil Comm. (Agentur für Investor Relations und Podcasts)
Green Ticker Tales
Greentickertales
Curiosity Chronicle
Sahil Bloom
今日股市 | 薪伊谈股票投资
薪伊Elaine
Handelsblatt Morning Briefing - News aus Wirtschaft, Politik und Finanzen
Friederike Hofmann, Sven Prange und die Handelsblatt Redaktion, Handelsblatt
Negocios
BioCentury
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank...
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in S...
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The...
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing th...
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on The BioCen...
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, accordi...
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-fou...
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting s...
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI...
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower re...
Caution: This episode of The BioCentury Show contains strong language.In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slo...
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypoth...
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move id...
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to con...
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary s...
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by techno...
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.If you c...
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic ca...
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though...
Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of bio...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.